Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 6/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 12/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498598 | 1.00 | KCNK3 (1.00) | KCNK3KCNK9KCNA5BRAFPDE2A | |
| SCHEMBL498597 | 1.00 | KCNK3 (1.00) | KCNK3KCNK9KCNA5BRAFPDE2A | |
| SCHEMBL29761432 | 1.00 | KCNK3 (1.00) | KCNK3KCNK9KCNA5BRAFPDE2A | |
| SCHEMBL13480244 | 0.90 | KCNK3 (0.82) | KCNK3KCNK9KCNA5BRAF | |
| SCHEMBL8294602 | 0.90 | KCNK3 (0.81) | KCNK3KCNK9KCNA5BRAF | |
| SCHEMBL12201305 | 0.83 | KCNA5 (0.87) | KCNK3KCNK9KCNA5 | |
| SCHEMBL14498283 | 0.78 | KCNA5 (0.77) | KCNK3KCNK9KCNA5 | |
| SCHEMBL27620171 | 0.78 | KCNK3 (0.66) | KCNK3KCNK9KCNA5PDE2A | |
| SCHEMBL14267638 | 0.77 | KCNA5 (1.00) | KCNK3KCNK9KCNA5PDE2A | |
| SCHEMBL31478899 | 0.75 | KCNK3 (0.61) | KCNK3KCNK9PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | KCNK3 18/4885KCNK9 106/4885KCNA5 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.